Evolent Health
EVH
131 hedge funds and large institutions have $921M invested in Evolent Health in 2017 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 49 increasing their positions, 30 reducing their positions, and 17 closing their positions.
360% more call options, than puts
Call options by funds: $5.97M | Put options by funds: $1.3M
112% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 17
111% more capital invested
Capital invested by funds: $435M → $921M (+$485M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
63% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 30
22.89% more ownership
Funds ownership: 55.96% → 78.85% (+23%)
11% more funds holding
Funds holding: 118 → 131 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$53.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$40.7M |
| 4 |
PA
Perceptive Advisors
New York
|
+$21.8M |
| 5 |
Millennium Management
New York
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$34.1M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$9.85M |
| 3 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$7.4M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$5.93M |
| 5 |
PC
Pier Capital
Stamford,
Connecticut
|
-$4.64M |
EVH Hedge Fund Activity: Q1 2017 in Review
131 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q1 2017, worth a combined $921M — up 111% from $435M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new EVH positions and 17 closed out — a net gain of 19 holders — while 49 added to existing stakes and 30 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $53.6M. The largest seller was Granahan Investment Management, cutting an estimated $34.1M.
- 131 institutional investors held Evolent Health (EVH) as of Q1 2017, up from 118 in Q4 2016.
- Funds reported $921M of Evolent Health stock for Q1 2017, up 111% quarter-over-quarter.
- 36 funds opened new Evolent Health positions in Q1 2017 and 17 closed out, a net change of +19 holders.
- The largest Evolent Health buyer in Q1 2017 was JP Morgan Chase, an estimated $53.6M added.
- The largest Evolent Health seller in Q1 2017 was Granahan Investment Management, an estimated $34.1M sold.
Based on aggregated 13F filings for Q1 2017.